On an earnings call earlier this week, Pfizer CEO Ian Read said that the company will be returning to “business as normal” on its drug pricing in January, after having agreed to hold off on price increases earlier this year following pressure from the Trump administration.
On an earnings call earlier this week, Pfizer CEO Ian Read said that the company will be returning to “business as normal” on its drug pricing in January, after having agreed to hold off on price increases earlier this year following pressure from the Trump administration.
Drug pricing has been a key issue in the political arena leading up to the midterm elections next week. President Trump, together with HHS Secretary Alex Azar, have narrowed their focus to lowering drug prices for American patients through numerous actions and efforts, some of which were outlined in the American Patients First blueprint.
To underscore the efforts to address drug prices, Trump began to put pressure on pharmaceutical companies individually. Following a conversation between Read and Trump in July, Pfizer announced that it would hold off on a planned price increase. Pfizer was not the only company to halt price hikes; around the same time, Merck, Novartis, and Roche also agreed to hit pause on price increases for the rest of 2018.
“Pfizer is rolling back price hikes, so American patients don’t pay more. We applaud Pfizer for this decision and hope other companies do the same. Great news for the American people!” tweeted Trump at the time.
However, on the latest earnings call, Read signaled that the agreement to hold off on price hikes would end at the end of 2018, at which point the company will return to pricing based on the market. “We price to the marketplace, we price competitively,” said Read.
Of note, the administration is not relying solely on voluntary actions from pharmaceutical companies to lower drug prices. Last week, Trump unveiled a new plan that aims to reduce Medicare’s costs for prescription drugs where CMS could set its prices for some drugs, including biologics, based on the prices paid in other nations.
The plan was met with mixed responses from industry stakeholders. CMS is currently taking comments on the pricing model until Monday, December 31, 2018, after which it plans to issue a proposed rule in spring 2019.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.